Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allogeneic CD19 CAR-T cell (Shenzhen University General Hospital)
- Development stage
- Unknown
- Lead developer
- Shenzhen University General Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Allogeneic CD19 CAR-T cell therapy is an investigational "off-the-shelf" cellular immunotherapy developed by Shenzhen University General Hospital for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). The therapy utilizes T cells from healthy donors that are genetically engineered to express a chimeric antigen receptor (CAR) targeting the CD19 antigen, a protein consistently expressed on the surface of B-cell malignancies. This allogeneic approach is designed to overcome the logistical and biological challenges of autologous CAR-T therapies, such as the lengthy manufacturing process and the potential for poor T-cell quality in heavily pretreated patients, by providing a readily available product with consistent potency.
- Other names
- Allogeneic CD19 CAR-T cellsAllogeneic CD19 CAR-T cell therapy
02
Targets
Beyond the preview
Go deeper on Allogeneic CD19 CAR-T cell (Shenzhen University General Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allogeneic CD19 CAR-T cell (Shenzhen University General Hospital).